Eli Lilly partner urges investors to look beyond biotech turmoil
Look at the future prospects, not the losses, says the CEO of a newly listed Chinese biotech company that’s developing anti-cancer drugs with Indianapolis-based Eli Lilly and Co.
Health Care Businesses
Articles
Trump focusing on drug prices, high among voters’ concerns
President Donald Trump is linking the drug prices Americans complain about to one of his longstanding grievances: foreign countries the president says are taking advantage of U.S. research breakthroughs.
Opioid alternative from Lilly, Pfizer shows promise in study
The experimental drug eased arthritis pain in hard-to-treat patients without major safety concerns, a key step in creating a new class of medications that may one day offer an alternative to narcotics.
Endocyte acquisition gives Novartis key therapy—at almost 200 times its last price
One year ago, Indiana-based Endocyte Inc. bought the rights to a prostate cancer treatment for $12 million, plus future considerations. On Thursday, Novartis AG agreed to pay almost 200 times that amount to acquire Endocyte and the experimental therapy.
Firm planning $25M behavioral health hospital in Plainfield
The standalone, two-story facility is expected to offer a wide array of inpatient and outpatient services, including addiction treatment, counseling and psychiatric intensive care.
Elanco shares lowest since IPO after failing to get consensus buy rating
Shares in Elanco Animal Health Inc. slipped as much as 3.3 percent Monday morning after lead managers and other banks involved in its recent initial public offering started coverage on the animal health company.
Lilly might market diabetes drug for obesity after research results
Eli Lilly and Co.’s stock jumped Thursday after midstage research on an experimental diabetes drug showed significant weight loss in patients. The news took a toll on shares of rival Novo Nordisk.
Roche using data-driven diagnostic tools to reshape patient care
The company, which employs more than 3,000 on the northeast side, has been struggling on the diabetes side of its business. To bounce back, it is investing heavily in diagnostics, and is working to commercialize several products it hopes will be game-changers.
Big gymnasium in downtown corporate campus to be demolished
The owner of the 40,000-square-foot gym says upgrading the facility would cost tens of millions of dollars, and that the cost to maintain it is greater than the property’s value.
Migraine drug from Eli Lilly approved by FDA
Eli Lilly and Co. received clearance Thursday from U.S. regulators for a new migraine drug that will be the third in a promising class of therapies for patients who suffer from the recurrent, painful headaches.
Lilly’s Elanco animal-health business raises $1.5 billion in IPO
Greenfield-based Elanco Animal Health Inc. raised more than expected in its initial public offering, pricing its shares above the marketed price range.
Competitor beats Lilly to market with migraine drug approval
The competition for the multi-billion dollar migraine market is set to heat up with the FDA expected to decide on Lilly’s migraine therapy next month.
Hc1.com dives deeper into opioid data, precision care
The Indianapolis medical-software firm recently raised $10 million in venture funding and is launching two major products in one month.
Lilly’s Elanco spinoff expected to raise up to $1.45 billion in IPO
The Greenfield-based animal health unit is gearing up for independence after 65 years as part of drugmaker Eli Lilly and Co. But Elanco has been struggling, and top management will have to work hard to stabilize the operation.
Q&A: What’s behind the growing scrutiny of insulin prices?
The American Medical Association recently called on regulators to monitor competition among the three drugmakers who control the market—Indianapolis-based Eli Lilly and Co., Denmark-based Novo Nordisk and Paris-based Sanofi.
China cuts red tape, increases potential for breakthrough medicines
After decades of being starved of innovative treatments for serious conditions like cancer, diabetes and kidney disease, China’s 1.4 billion people are becoming a prime target for Eli Lilly and other pharmaceutical companies.
Eli Lilly’s animal-health business files for initial public offering
Elanco Animal Health Inc. could see a market value of as much as $20 billion, according to Bloomberg Intelligence. At that valuation, a share sale could raise as much as $5 billion.
Firm crusades for insurers to cover alternative therapies
Carmel-based American Specialty Health specializes in connecting patients with chiropractors, acupuncturists, physical therapists and others who treat pain without using pharmaceutical drugs.
Lilly shares hit highest point in 18 years after Elanco decision
The run-up in share price seems to reflect investor sentiment that the Indianapolis drugmaker has turned a corner after more than a decade of struggling to launch new medicines.
Fraud scheme’s ‘CFO’ gets 5 years in prison; lesser player gets 4 months
Steven Ganote, who prosecutors say was a key player in the massive American Senior Communities overbilling and kickback scheme, was also ordered to pay $7 million in restitution.